Top medicines panel benefits from second consumer representative
The appointment of a second consumers representative to the Pharmaceutical Benefits Advisory Committee recognises the value of the consumer perspective in vital decisions about access to medicines, the Consumers Health Forum said today.
“We are delighted that Bel Harper has been appointed to the PBAC which recommends to Government which new medicines should receive subsidies,” Leanne Wells, CEO of the Consumers Health Forum, said.
“Ms Harper is a member of the CHF board and brings more than 15 years’ experience in program development, managing not-for-profit organisations and community advocacy.
“She joins Jo Watson, deputy chair of CHF, who has served on the PBAC for four years.
“Having people on the PBAC like Jo and Bel, who have both spent many years advocating for health consumers, deepens the assessment and consideration that the PBAC devotes to its important decision-making,” Ms Wells said.
“The PBAC has an outstanding role in Australian healthcare as one of the entities which actually examines the cost effectiveness of therapies before recommending government spending.
“It means that Australia has a world-best approach that ensure access to new medicines and that we are spending public money on medicines that are best value for money.”